Abstract:The CYP2A6 gene spans a region of approximately 6 kb pairs consisting of 9 exons and has been mapped to the long arm of chromosome 19 (between 19q12 and 19q13.2). The CYP2A6 protein has 494 amino acids and is an important hepatic Phase I enzyme that metabolizes approximately 3% of therapeutic drugs (n > 30; e.g. valproic acid, pilocarpine, tegafur, fadrozole, ifosfamide, cyclophosphamide, nicotine, tamoxifen, promazine, propofol, and cisapride), environmental toxicants (e.g. gasoline additives), and many procarcinogens such as nitrosamines and aflatoxin B(1). This enzyme also participates in the biotransformation of several endogenous compounds such as retinoid acids and steroids. Because CYP2A6 is responsible for 70-80% of the initial metabolism of nicotine, CYP2A6 has been proposed to be a novel target for smoking cessation. Site-directed mutagenesis and homology modeling studies have identified a number of amino acids (e.g. F300, A301, S208, S369, and L370) that play a role in substrate recognition and binding. CYP2A6 shows a crystal structure with a compact, hydrophobic active site with Asn297 serving as one hydrogen bond donor and orienting substrates for regio-selective oxidation. CYP2A6 contains the second smallest active site cavity among the human CYPs with known structures. The regulation mechanism of CYP2A6 expression is not fully understood, but available data suggest that several nuclear receptors including constitutive androstane receptor, pregnane X receptor and glucocorticoid receptor are involved in its regulation. Pilocarpine and tranylcypromine are commonly used as selective competitive inhibitors of CYP2A6. Selegiline, methoxsalen, (R)-(+) menthofuran and decursinol angelate are mechanism-based inhibitors of CYP2A6. Both in vitro and in vivo studies have demonstrated a wide (20- to >100-fold) interindividual variation in CYP2A6 expression and activity, which is due primarily to genetic polymorphisms in the CYP2A6 gene, but CYP2A6 activity is also modified by certain drugs and pathological and environmental factors. To date, more than 36 variant alleles (*1B through *37) of the CYP2A6 gene have been identified. There have been 278 SNPs found in the CYP2A6 upstream sequence, 8 introns and 9 exons in NCBI dbSNP. Polymorphism of CYP2A6 has been associated with smoking behavior, drug clearance and lung cancer risk. Further studies are warranted to explore the role of CYP2A6 in clinical practice, drug development and toxicology.

Cytochrome P450 2C8 and Drug Metabolism.

Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms

Genetic Polymorphism of Cytochrome P450 and Drug Metabolism

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Human Hepatic Cytochrome P450 2C Metalloenzymes and Drug Metabolism

Progress in relationship of cytochrome P450 1A2 genetic polymorphism,substance metabolism and carcinogenesis

Recent Advance of Cytochrome P450 2C9

Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2

Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development

Polymorphisms of Human Cytochrome P450 2c9 and the Functional Relevance

Progress in research of cytochrome P450 3A4 gene polymorphism

Advance in Genetic Polymorphism of Cytochrome P450 2C19

Cytochrome P450 Enzymes and Drug Metabolism in Humans

Structural and Functional Insights into CYP2C8.3: A Genetic Polymorph of Cytochrome P450 2C8

New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part I.

Drug-Metabolizing Enzyme CYP2D6 Polymorphism and Phenotypes

Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance.

Advances in Study of CYP2B6 Gene Polymorphisms and Its Functional Significances

Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6

Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: Focus on the regulation of gene expression and enzyme activity

Drugs As CYP3A Probes, Inducers, and Inhibitors